Protalix Ltd.

Liat Fux

Yoseph Shaaltiel

Avidor Shulman

Tali Kizhner

Ilya Ruderfer

Uri Hanania

Yulia Matiuhin

Lilach Chen Zeltsburg

Yulia Ugortsev

Hagit Neta

Sivan Gelley

Elad Lavee Laviad

Modified DNase I protein in which one or more amino acids of a DNase I protein are modified non-cellularly, are provided. The modified DNase I protein exhibits a DNA hydrolytic activity in the presence of actin and an improved DNA hydrolytic activity compared to a homologous non-modified DNase I protein. Processes of preparing the modified DNase I protein and uses thereof in, for example, reducing a DNA content in sputum and/or in treating a disease or condition associated with excess extracellular DNA in a fluid, secretion or tissue of a subject, are also provided.

Modified DNase and uses thereof

DNase I formulations for pulmonary administration and, more particularly, but not exclusively, a dry powder formulation comprising, as an active ingredient, human DNase I, methods, dry powder inhalation devices and systems for the therapeutic use thereof are provided.

Dry powder formulations of dNase I

An inhalable pharmaceutical composition for pulmonary administration comprising human DNase I and a liquid carrier and, more particularly, but not exclusively, to methods, liquid pharmaceutical inhalation devices and systems for the therapeutic use thereof are provided.

Inhalable liquid formulations of DNase I

Growing community of inventors

Kiryat Motzkin, Israel

Liat Fux